The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Subanalysis.

This document is a subanalysis of the ANNEXA-4 study, which investigated the efficacy and safety of Andexanet Alfa (AA) in patients with acute gastrointestinal (GI) bleeding while taking factor Xa (FXa) inhibitors. The study found that AA was effective in achieving hemostasis in 80% of patients with FXa inhibitor-associated acute major bleeding. The most common site of bleeding was the stomach, with peptic ulcer disease as the most frequent cause. The study also reported a 12% mortality rate within 30 days of anticoagulant-related major GI bleeding. However, the study's limitations, such as the lack of a control group and small sample size, should be considered when interpreting the results. [Extracted from the article]